GENTAMICIN SULFATE | A064048 | BAUSCH AND LOMB INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Altaire Pharmaceuticals, Inc. - Citizen Petition FDA-2013-P-0670 · 3 docket documents Altaire Pharmaceuticals, Inc. filed this citizen petition on June 4, 2013, under Section 505(j) of the Federal Food, Drug and Cosmetic Act requesting that the FDA amend the Orange Book to designate Gentak® Gentamicin Sulfate Ophthalmic Solution, EQ 0.3% base, ANDA 064163 held by Akorn Inc. as a refe | 505(q) | 2013-06-18 | Granted | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.7363
per ml
Lowest NADAC/Unit
$0.7363
per ml
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 24208058060GENTAMICIN 0.3% EYE DROP | $0.7363 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.